Education

Personal Finance How To Use TipRanks TipRanks Labs Webinar Center Glossary FAQs

About Us

About TipRanks Contact Us Careers Reviews Mobile APP

Working with TipRanks

Enterprise Solutions Advertise with Us Top Online Brokers Become an Affiliate TipRanks News Wire

TOOLS

Top Smart Score Stocks

STOCKS

Research Tools

Most Visited Websites

Daily Feeds

Daily Analyst Ratings

Daily Insider Trading Tracker

Calendars

Economic Indicators

Economic Indicators Center

Inflation Rate

Unemployment Rate

Federal Funds Rate

Class Actions

Calculators

Dividend Calculator

Dividend Yield Calculator

Options Profit Calculator

Dollar Cost Averaging

Technical Analysis Screener

Dividend Center

Best Dividend Stocks

Popular

Best High Yield Dividend Stocks

Dividend Aristocrats

Dividend Stock Comparison

New

Dividend Calculator

Dividend Returns Comparison

Dividend Calendar

Top Analysts

Top Financial Bloggers

Top-Performing Corporate Insiders

Top Hedge Fund Managers

Top Research Firms

Top Individual Investors

News

Portfolio

Personal Finance Center

Mortgages

Loans

Investing & Retirement

Spending & Savings

Calculators

Compound Interest Calculator

Student Loan Calculator

401k Retirement Calculator

Education

About Us

Working with TipRanks

Xbrane Biopharma AB (DE:7XB)

BERLIN:7XB

7XB

Xbrane Biopharma AB

RESEARCH TOOLS

Top Smart Score Stocks

Stock Screener

reports

Holding DE:7XB?

Track your performance easily

Link Broker

Xbrane Biopharma AB (7XB) Income Statement

1 Followers

Xbrane Biopharma AB Income Statement

Last quarter (Q4 2022), Xbrane Biopharma AB's total revenue was kr20.86M, an increase of 80.89% from the same quarter last year. In Q4, Xbrane Biopharma AB's net income was kr-60.73M. See Xbrane Biopharma AB’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	kr 57.62M	kr 57.62M	kr 11.53M	kr 7.09M	kr 600.00K	kr 112.95M
Cost of Revenue	-	kr 0.00	kr 0.00	kr 0.00	kr 18.27M	kr 15.91M
Gross Profit	kr 57.62M	kr 57.62M	kr 11.53M	kr 7.09M	kr -17.67M	kr 97.05M
Operating Expense	kr 210.27M	kr 210.27M	kr 191.93M	kr 223.74M	kr 162.24M	kr 107.52M
Operating Income	kr -152.65M	kr -152.65M	kr -180.40M	kr -216.65M	kr -179.91M	kr -10.47M
Net Non Operating Interest Income Expense	kr -2.30M	kr -2.29M	kr -2.64M	kr -691.00K	kr -1.42M	kr -1.70M
Other Income Expense	-	-	-	-	-	-
Pretax Income	kr -168.51M	kr -168.51M	kr -183.23M	kr -218.13M	kr -187.99M	kr -13.12M
Tax Provision	-	kr 0.00	kr 0.00	kr 0.00	kr 0.00	kr 121.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	kr -172.51M	kr -172.51M	kr -188.38M	kr -226.03M	kr -187.99M	kr -13.24M
Basic EPS	kr -6.82	kr -6.75	kr -7.98	kr -12.48	kr -14.84	kr -2.02
Diluted EPS	kr -6.82	kr -6.75	kr -7.98	kr -12.48	kr -14.84	kr -2.02
Basic Average Shares	kr 102.21M	kr 25.57M	kr 23.59M	kr 18.11M	kr 11.19M	kr 6.55M
Diluted Average Shares	kr 102.21M	kr 25.57M	kr 23.59M	kr 18.11M	kr 11.19M	kr 6.55M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	kr 210.27M	kr 210.27M	kr 191.93M	kr 223.74M	kr 180.51M	kr 123.42M
Net Income From Continuing And Discontinued Operation	kr -172.51M	kr -172.51M	kr -188.38M	kr -226.03M	kr -187.99M	kr -13.24M
Normalized Income	kr -168.51M	kr -168.51M	kr -183.23M	kr -218.13M	kr -188.01M	kr -12.55M
Interest Expense	kr 2.58M	kr 2.58M	kr 2.64M	kr 691.00K	kr 1.46M	kr 1.75M
EBIT	kr -165.93M	kr -165.93M	kr -180.59M	kr -217.44M	kr -186.53M	kr -11.37M
EBITDA	kr -165.93M	kr -165.93M	kr -167.59M	kr -210.87M	kr -179.21M	kr -7.05M

Currency in SEK

Xbrane Biopharma AB Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing